ESGO 2021 - 22nd European Gynaecological Oncology Congress of the European Society of Gynaecological Oncology
Oct 23 - Oct 25, 2021 | PragueCzech Republic
LARVOL is not affiliated with 22nd European Gynaecological Oncology Congress of the European Society of Gynaecological Oncology and all trademarks, logos, and brand names are property of their respective owners
Showing 52 abstracts linked to Trials
Sentinel lymph-node biopsy in early-stage cervical cancer: the 4-year follow-up results of the senticol 2 trial
Dostarlimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study
SENTIX - Accuracy of preoperative local staging in the Sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063)
Results of NSGO-OV-UMB1/ENGOT-OV30 study: A phase II study of durvalumab and oleclumab in patients with relapsed ovarian cancer (OC)
Molecular profiling of NSMP high-risk endometrial cancers of the PORTEC-3 trial – prognostic refinement and druggable targets
[VIRTUAL] STELLA-2 trial: Surgical complications comparing extraperitoneal vs transperitoneal MIS aortic staging in early stage ovarian and endometrial cancer
[VIRTUAL] Sensitivity and false negativity of SLN frozen section histological evaluation in the Sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063)
[VIRTUAL] Lower-limb lymphedema after sentinel lymph node biopsy in cervical cancer patients
Dose modification for Chinese patients on niraparib maintenance treatment for platinum-sensitive recurrent ovarian cancer: A post hoc analysis
Safety and quality of life of first-line maintenance olaparib plus bevacizumab in older patients with advanced ovarian cancer in the PAOLA-1 trial
Efficacy and safety of maintenance olaparib by patient age in non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer in OPINION
The impact of intensive follow-up on health-related quality of life and costs in endometrial cancer patients: data from the TOTEM trial NCT00916708
Efficacy of niraparib by timing of Surgery and residual disease: Post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
Survival in advanced-stage ovarian carcinoma with high VEGF-A expression after addition of bevacizumab. Results from the German ICON7 patient cohort
Randomised Phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer